ECD Proteins
SKU: PME100095 Target: Her2 Tag: C-6×His Tag
Price: 10μg $85.00; 50μg $310.00 ; 100 μg $460.00
ECD Proteins
SKU: PME100665 Target: Her2 Tag: C-Human Fc Tag
Price: 10μg $78.00; 50μg $310.00 ; 100 μg $460.00
ECD Proteins
SKU: PME-C100074 Target: Her2 Tag: C-10×His tag
Price: 10μg $78.00; 50μg $310.00 ; 100 μg $460.00
Posts found
HER2 | A Key Target in Solid Tumor Therapy
On November 20, 2024, Jazz Pharmaceuticals announced that the bispecific antibody Zanidatamab had received accelerated [...]
Feb
From “Immuno-Oncology Star” to Technology Race A Comprehensive Overview of PD-1 Targeted Drug Modalities
Over the past year, the PD-1 immunotherapy landscape has once again witnessed intensive progress. From [...]
Dec
November Biopharma BD Highlights: Key M&A and Licensing Deals in 2025
In November 2025, business development (BD) activities in the biopharmaceutical industry slowed slightly compared with [...]
Dec
Domain-Specific Protein Fragments in Therapeutic Antibody Discovery
Using multiple recombinant protein fragments from the same target—such as extracellular domains, functional regions, and [...]
Dec
Unlocking Membrane Proteins: The Key to Life’s Gateway
Membrane proteins are molecules that are critically important for life, undertaking key functions such as [...]
Nov
Breaking Down WCLC 2025 The Most Talked-About Lung Cancer Targets
The 2025 World Lung Cancer Conference (WCLC) will be held by the International Association for [...]
Sep
Dual-Payload ADCs: The Next Big Thing in the ADC Arena
Efforts to improve traditional ADCs have primarily focused on the three key components: the antibody, [...]
Apr
Popular Targets in the Bispecific ADC Pipeline
At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such [...]
Apr
China’s Growing Impact on ADC Development at AACR 2025
The 2025 American Association for Cancer Research (AACR) Annual Meeting is set to take place [...]
Apr
Going Nuclear: The Boom of Radiopharmaceutical Targets in 2024
In 2024, the radiopharmaceutical sector has seen a flurry of activity in mergers and acquisitions. [...]
Oct